"Designing Growth Strategies is in our DNA"

Contact Dermatitis – Pipeline Review, 2019

Region : Global | Published Date: Upcoming | Report ID: FBI101276| Status : Pipeline



Contact dermatitis is a type of skin inflammation caused by an allergic reaction due to contact with a substance. Symptoms of this most common form of eczema include a red rash, blisters, itching, swelling or burning sensation. There are many allergens that can trigger contact dermatitis like, soap, nickel metal, cosmetics, therapeutic ointment, acid burns, diapers among others. There are currently two forms of contact dermatitis, allergic contact dermatitis caused due to an allergic reaction to a substance and irritant contact dermatitis caused due to exposure to toxic chemicals. 

Since contact dermatitis is curable skin eczema and the treatment options comprises of medications applied topically and in severe cases administered orally. Oral antihistamine drugs like cetirizine and fexofenadine are prescribed to treat contact dermatitis. In the majority of the cases, corticosteroid ointment is applied to alleviate the skin inflammation.

Research institutes and pharmaceutical companies are developing various treatment options form contact dermatitis most of which have completed their clinical studies. For instance, Innovaderm Research Inc. is currently studying EB01 Cream which is in Phase 2 clinical trial for the treatment of chronic allergic contact dermatitis.

At present, around 50% of the pipeline candidates for contact dermatitis are in the phase-2 clinical stage. More than half of the studies are sponsored by industry.

Report Description

The report on ‘Contact Dermatitis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for contact dermatitis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for contact dermatitis.

The report on ‘Contact Dermatitis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

  • Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
  • Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
  • Overview of dormant and discontinued pipeline products
  • Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
  • Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

  • All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
  • Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

  • Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Contact dermatitis
  • Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
  • Identify the focus of leading players in relation to R&D for Contact dermatitis
  • Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
  • Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary


  • 2050

Healthcare Clients

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.